Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Diabetes

  Free Subscription


Articles published in Diabetes Obes Metab

Retrieve available abstracts of 385 articles:
HTML format
Text format



Single Articles


    April 2019
  1. KOSHIZAKA M, Ishikawa K, Ishibashi R, Maezawa Y, et al
    Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomised contro
    Diabetes Obes Metab. 2019 Apr 17. doi: 10.1111/dom.13750.
    PubMed     Text format     Abstract available


  2. PETTUS J, Gill J, Paranjape S, Stewart J, et al
    Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
    Diabetes Obes Metab. 2019 Apr 17. doi: 10.1111/dom.13751.
    PubMed     Text format     Abstract available


  3. XIA J, Song Y, Rawal S, Wu J, et al
    Vitamin D Status during Pregnancy and the Risk of Gestational Diabetes Mellitus: A Longitudinal Study in a Multiracial Cohort.
    Diabetes Obes Metab. 2019 Apr 17. doi: 10.1111/dom.13748.
    PubMed     Text format     Abstract available


  4. ADIELS M, Taskinen MR, Bjornson E, Andersson L, et al
    Role of apolipoprotein C-III overproduction in diabetic dyslipidemia.
    Diabetes Obes Metab. 2019 Apr 10. doi: 10.1111/dom.13744.
    PubMed     Text format     Abstract available


  5. GIUGLIANO D, De Nicola L, Maiorino MI, Bellastella G, et al
    Type 2 diabetes and the kidney: insights from cardiovascular outcome trials.
    Diabetes Obes Metab. 2019 Apr 10. doi: 10.1111/dom.13743.
    PubMed     Text format     Abstract available


  6. WITTBRODT E, Chamberlain D, Arnold SV, Tang F, et al
    Eligibility of patients with type 2 diabetes for SGLT-2 inhibitor cardiovascular outcomes trials: an assessment using the Diabetes Collaborative Registry.
    Diabetes Obes Metab. 2019 Apr 10. doi: 10.1111/dom.13738.
    PubMed     Text format     Abstract available


  7. HALLBERG SJ, Dockter NE, Kushner JA, Athinarayanan SJ, et al
    Improving the Scientific Rigor of Nutritional Recommendations for Adults with Type 2 Diabetes: A Comprehensive Review of the American Diabetes Association Guidelines Recommended Eating Patterns.
    Diabetes Obes Metab. 2019 Apr 3. doi: 10.1111/dom.13736.
    PubMed     Text format     Abstract available


  8. TSUJIMOTO T, Kajio H
    No beneficial effects of aspirin on secondary cardiovascular prevention in patients with type 2 diabetes taking non-steroidal anti-inflammatory drugs.
    Diabetes Obes Metab. 2019 Apr 3. doi: 10.1111/dom.13737.
    PubMed     Text format     Abstract available


  9. PATORNO E, Gopalakrishnan C, Brodovicz KG, Meyers A, et al
    Cardiovascular safety of linagliptin compared to other oral glucose lowering agents in patients with type 2 diabetes: a sequential monitoring program in routine care.
    Diabetes Obes Metab. 2019 Apr 2. doi: 10.1111/dom.13735.
    PubMed     Text format     Abstract available


  10. SPANOPOULOS D, Okhai H, Zaccardi F, Tebboth A, et al
    Temporal variation of renal function in people with type 2 diabetes mellitus: a retrospective UK Clinical Practice Research Datalink cohort study.
    Diabetes Obes Metab. 2019 Apr 2. doi: 10.1111/dom.13734.
    PubMed     Text format     Abstract available


  11. SEIDU S, Topsever P, Hambling CE, Cos FX, et al
    Deintensification in older patients with type 2 diabetes: a systematic review of approaches, rates and outcomes.
    Diabetes Obes Metab. 2019 Apr 1. doi: 10.1111/dom.13724.
    PubMed     Text format     Abstract available


  12. ARONSON R, Abitbol A, Tweden KS
    First Assessment of the Performance of an Implantable CGM System Through 180 Days in a Primarily Adolescent Population with Type I Diabetes.
    Diabetes Obes Metab. 2019 Apr 1. doi: 10.1111/dom.13726.
    PubMed     Text format     Abstract available


  13. YANG W, Ma J, Yuan G, Li L, et al
    Determining the optimal fasting glucose target for patients with type 2 diabetes: results of the multicentre, open-label, randomized-controlled FPG GOAL trial.
    Diabetes Obes Metab. 2019 Apr 1. doi: 10.1111/dom.13733.
    PubMed     Text format     Abstract available


  14. DASH S, Leiter LA
    Residual cardiovascular risk among people with diabetes.
    Diabetes Obes Metab. 2019;21 Suppl 1:28-38.
    PubMed     Text format     Abstract available


  15. BENGALURU JAYANNA M, Robinson JG
    The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of "real world" practice in people with diabetes.
    Diabetes Obes Metab. 2019;21 Suppl 1:17-27.
    PubMed     Text format     Abstract available


  16. DIJK W, Cariou B
    Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Diabetes Obes Metab. 2019;21 Suppl 1:39-51.
    PubMed     Text format     Abstract available



  17. New frontiers in cardiovascular risk reduction: people with diabetes and dyslipidaemia.
    Diabetes Obes Metab. 2019;21 Suppl 1:5.
    PubMed     Text format    


  18. GONNA H, Ray KK
    The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes.
    Diabetes Obes Metab. 2019;21 Suppl 1:6-16.
    PubMed     Text format     Abstract available


    March 2019
  19. POLLOCK RF, Heller S, Pieber TR, Woo V, et al
    Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events - a Canadian setting (DEVOTE 9).
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13730.
    PubMed     Text format     Abstract available


  20. PETERS A, Piletic M, Ejstrud J, Salvesen-Sykes K, et al
    Baseline nocturnal glucose change: a predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes.
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13729.
    PubMed     Text format     Abstract available


  21. KLOECKER DE, Zaccardi F, Baldry E, Davies MJ, et al
    Efficacy of Low- and Very-Low-Energy Diets in people with Type 2 Diabetes Mellitus: A systematic review and meta-analysis of interventional studies.
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13727.
    PubMed     Text format     Abstract available


  22. SCHMIDT S, Christensen MB, Serifovski N, Damm-Frydenberg C, et al
    Low versus High Carbohydrate Diet in Type 1 Diabetes: A 12-week randomized open-label crossover study.
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13725.
    PubMed     Text format     Abstract available


  23. KOSTEV K
    Longitudinal Changes in HbA1c following Therapy Intensification after Inadequate Response to Two Oral Antidiabetic Agents in Patients with Type 2 Diabetes in Germany.
    Diabetes Obes Metab. 2019 Mar 25. doi: 10.1111/dom.13707.
    PubMed     Text format     Abstract available


  24. FREEMANTLE N, Jourdan S
    Comment on "A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes".
    Diabetes Obes Metab. 2019 Mar 22. doi: 10.1111/dom.13711.
    PubMed     Text format     Abstract available


  25. HELLER SR, DeVries JH, Wysham C, Hansen CT, et al
    Lower rates of hypoglycaemia in older people with type 2 diabetes when using insulin degludec versus insulin glargine U100: results from SWITCH 2.
    Diabetes Obes Metab. 2019 Mar 20. doi: 10.1111/dom.13708.
    PubMed     Text format     Abstract available


  26. YANG W, Ma J, Hong T, Liu M, et al
    Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: a phase 3, open-label, 2:1 randomized, treat-to-target trial.
    Diabetes Obes Metab. 2019 Mar 14. doi: 10.1111/dom.13703.
    PubMed     Text format     Abstract available


  27. VERMA S, Bain SC, Monk Fries T, Mazer CD, et al
    Duration of Diabetes and Cardiorenal Efficacy of Liraglutide and Semaglutide: A Post Hoc Analysis of the LEADER and SUSTAIN 6 Clinical Trials.
    Diabetes Obes Metab. 2019 Mar 9. doi: 10.1111/dom.13698.
    PubMed     Text format     Abstract available


  28. CHEN Y, Yuan Z, Lu J, Eliaschewitz FG, et al
    Randomised study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the China Population From the BERSON Clinical Trial.
    Diabetes Obes Metab. 2019 Mar 9. doi: 10.1111/dom.13700.
    PubMed     Text format     Abstract available


  29. RUSSELL-JONES D, Dauchy A, Delgado E, Dimitriadis G, et al
    Take Control: A Randomized Trial Evaluating the Efficacy and Safety of Self- Versus Physician-Managed Titration of Insulin Glargine 300 U/mL (Gla-300) in Patients with Uncontrolled Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Mar 8. doi: 10.1111/dom.13697.
    PubMed     Text format     Abstract available


  30. PRATLEY RE, Emerson SS, Franek E, Gilbert MP, et al
    Cardiovascular safety and severe hypoglycaemia benefit of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: results from DEVOTE (DEVOTE 7).
    Diabetes Obes Metab. 2019 Mar 8. doi: 10.1111/dom.13699.
    PubMed     Text format     Abstract available


  31. KIM K, Unni S, Brixner DI, Thomas SM, et al
    Longitudinal Changes in HbA1c following Treatment Intensification after Inadequate Response to Two Oral Antidiabetic Agents in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Mar 7. doi: 10.1111/dom.13694.
    PubMed     Text format     Abstract available


  32. BAILEY TS, Zhou FL, Gupta RA, Preblick R, et al
    Glycemic goal attainment and hypoglycemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naive cohort study.
    Diabetes Obes Metab. 2019 Mar 6. doi: 10.1111/dom.13693.
    PubMed     Text format     Abstract available


  33. DUNKLEY AJ, Fitzpatrick C, Gray LJ, Waheed G, et al
    Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: a UK multi-site 12-month prospective observational study.
    Diabetes Obes Metab. 2019 Mar 6. doi: 10.1111/dom.13690.
    PubMed     Text format     Abstract available


  34. LAN NS, Fegan PG, Yeap BB, Rankin JM, et al
    Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: act now to reduce it.
    Diabetes Obes Metab. 2019 Mar 4. doi: 10.1111/dom.13689.
    PubMed     Text format     Abstract available


  35. ARAKI E, Yamashita S, Arai H, Yokote K, et al
    The Efficacy and Safety of Pemafibrate in Patients with Type 2 Diabetes and Elevated Triglyceride levels: 52-Week Data From The PROVIDE Study.
    Diabetes Obes Metab. 2019 Mar 4. doi: 10.1111/dom.13686.
    PubMed     Text format     Abstract available


  36. JI L, Liu Y, Miao H, Xie Y, et al
    Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
    Diabetes Obes Metab. 2019 Mar 4. doi: 10.1111/dom.13681.
    PubMed     Text format     Abstract available


  37. DENNIS JM, Henley WE, McGovern AP, Farmer AJ, et al
    Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017.
    Diabetes Obes Metab. 2019 Mar 3. doi: 10.1111/dom.13687.
    PubMed     Text format     Abstract available


  38. MEIFFREN G, Herbrand T, Anastassiadis E, Klein O, et al
    Better glycemic control with BioChaperone Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM).
    Diabetes Obes Metab. 2019 Mar 3. doi: 10.1111/dom.13685.
    PubMed     Text format     Abstract available


  39. UNGER J, Allison DC, Carlton M, Lakkole K, et al
    Trial design and baseline data for LIRA-PRIME: a randomized trial investigating the efficacy of liraglutide in controlling glycemia in type 2 diabetes in a primary care setting.
    Diabetes Obes Metab. 2019 Mar 3. doi: 10.1111/dom.13682.
    PubMed     Text format     Abstract available


  40. LORENZATTI AJ, Eliaschewitz FG, Chen Y, Lu J, et al
    Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial.
    Diabetes Obes Metab. 2019 Mar 1. doi: 10.1111/dom.13680.
    PubMed     Text format     Abstract available


  41. KAKU K, Isaka H, Toyoshima J, Sakatani T, et al
    Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2019 Mar 1. doi: 10.1111/dom.13679.
    PubMed     Text format     Abstract available


    February 2019
  42. RUGGENENTI P, Trillini M, P Barlovic D, Cortinovis M, et al
    Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
    Diabetes Obes Metab. 2019 Feb 22. doi: 10.1111/dom.13639.
    PubMed     Text format     Abstract available


  43. VILSBOLL T, Blevins TC, Jodar E, Poulter N, et al
    Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
    Diabetes Obes Metab. 2019 Feb 20. doi: 10.1111/dom.13675.
    PubMed     Text format     Abstract available


  44. JACOBI SF, Khajavi N, Kleinau G, Teumer A, et al
    Evaluation of a rare glucose-dependent insulinotropic polypeptide receptor variant in a patient with diabetes.
    Diabetes Obes Metab. 2019 Feb 19. doi: 10.1111/dom.13634.
    PubMed     Text format     Abstract available


  45. MENEGHINI LF, Mauricio D, Orsi E, Lalic NM, et al
    The Diabetes Unmet Need with basal insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
    Diabetes Obes Metab. 2019 Feb 15. doi: 10.1111/dom.13673.
    PubMed     Text format     Abstract available


  46. JOHNSTON SS, Ammann EM, Kashyap SR, Stokes A, et al
    Body Mass Index and Insulin Use as Identifiers of High-Cost Patients with Type 2 Diabetes: A Retrospective Analysis of Electronic Health Records Linked to Insurance Claims Data.
    Diabetes Obes Metab. 2019 Feb 15. doi: 10.1111/dom.13671.
    PubMed     Text format     Abstract available


  47. TUTTLE KR, Lakshmanan MC, Rayner B, Zimmermann AG, et al
    Body Weight and eGFR during Dulaglutide Treatment in Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7).
    Diabetes Obes Metab. 2019 Feb 14. doi: 10.1111/dom.13668.
    PubMed     Text format     Abstract available


  48. LYTVYN Y, Bjornstad P, Lovshin JA, Singh SK, et al
    The Association Between Uric Acid, Renal Hemodynamics and Arterial Stiffness Over the Natural History of Type 1 Diabetes.
    Diabetes Obes Metab. 2019 Feb 13. doi: 10.1111/dom.13665.
    PubMed     Text format     Abstract available


  49. PHILIS-TSIMIKAS A, Billings LK, Busch R, Morales Portillo C, et al
    Superior Efficacy of Insulin Degludec/Liraglutide versus Insulin Glargine U100 as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: a Randomized Clinical Trial in Patients with Uncontrolled Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Feb 13. doi: 10.1111/dom.13666.
    PubMed     Text format     Abstract available


  50. LEE DH, Chun EJ, Oh TJ, Kim KM, et al
    Effect of Cilostazol, a Phosphodiesterase-3 Inhibitor, on Coronary Artery Stenosis and Plaque Characteristics in Patients with Type 2 Diabetes (ESCAPE Study).
    Diabetes Obes Metab. 2019 Feb 13. doi: 10.1111/dom.13667.
    PubMed     Text format     Abstract available


  51. PARKINSON J, Tang W, Astrand M, Melin J, et al
    Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2019 Feb 12. doi: 10.1111/dom.13664.
    PubMed     Text format     Abstract available


  52. CANIVELL S, Mata-Cases M, Real J, Franch-Nadal J, et al
    Glycemic Control after Treatment Intensification in Patients with Type 2 Diabetes Uncontrolled on Two or More Non-Insulin Antidiabetic Drugs in a Real-World Setting.
    Diabetes Obes Metab. 2019 Feb 12. doi: 10.1111/dom.13663.
    PubMed     Text format     Abstract available


  53. MEZQUITA RAYA P, Ampudia Blasco FJ, Hunt B, Martin V, et al
    Evaluating the Long-Term Cost-Effectiveness of ideglira for type 2 diabetes in spain based on Real-World clinical evidence.
    Diabetes Obes Metab. 2019 Feb 11. doi: 10.1111/dom.13660.
    PubMed     Text format     Abstract available


  54. WEISMAN A, Tomlinson GA, Lipscombe LL, Perkins BA, et al
    Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: A retrospective, population-based cohort study.
    Diabetes Obes Metab. 2019 Feb 8. doi: 10.1111/dom.13656.
    PubMed     Text format     Abstract available


  55. FUECHTENBUSCH M, Aberle J, Heitmann E, Nicolay C, et al
    Weight loss in patients with type 2 diabetes (T2D) mellitus receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: An AWARD-4 post-hoc analysis across baseline body mass index subgroups.
    Diabetes Obes Metab. 2019 Feb 8. doi: 10.1111/dom.13658.
    PubMed     Text format     Abstract available


  56. BELL DSH, Goncalves E
    Heart Failure in the diabetic patient - epidemiology, etiology, prognosis, therapy and the effect of glucose lowering medications.
    Diabetes Obes Metab. 2019 Feb 5. doi: 10.1111/dom.13652.
    PubMed     Text format     Abstract available


  57. HE YL, Haynes W, Meyers CD, Amer A, et al
    The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
    Diabetes Obes Metab. 2019 Feb 5. doi: 10.1111/dom.13654.
    PubMed     Text format     Abstract available


  58. GARIANI K, Lebowitz D, Kressmann B, von Dach E, et al
    Oral Amoxicillin/Clavulanate for Treating Diabetic Foot Infections.
    Diabetes Obes Metab. 2019 Feb 5. doi: 10.1111/dom.13651.
    PubMed     Text format     Abstract available


  59. BOYE KS, Riddle MC, Gerstein HC, Mody R, et al
    Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials to the Overall Type 2 Diabetes Population in the United States.
    Diabetes Obes Metab. 2019 Feb 3. doi: 10.1111/dom.13649.
    PubMed     Text format     Abstract available


    January 2019
  60. TOYAMA T, Neuen BL, Jun M, Ohkuma T, et al
    Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2019 Jan 29. doi: 10.1111/dom.13648.
    PubMed     Text format     Abstract available


  61. MCGUIRE DK, Marx N, Johansen OE, Inzucchi SE, et al
    FDA Guidance on Antihyperglycemic Therapies for Type 2 Diabetes: One Decade Later.
    Diabetes Obes Metab. 2019 Jan 28. doi: 10.1111/dom.13645.
    PubMed     Text format     Abstract available


  62. YU L, Li X, Zhang Z, Du P, et al
    Dimorphic autoantigenic and protective effects of Reg2 peptide in the treatment of diabetic beta-cell loss.
    Diabetes Obes Metab. 2019 Jan 28. doi: 10.1111/dom.13644.
    PubMed     Text format     Abstract available


  63. LEITE NC, Viegas BB, Villela-Nogueira CA, Carlos FO, et al
    Efficacy of Diacerein in Reducing Liver Steatosis and Fibrosis in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized, Placebo-Controlled Trial.
    Diabetes Obes Metab. 2019 Jan 28. doi: 10.1111/dom.13643.
    PubMed     Text format     Abstract available


  64. CHARYTAN DM, Solomon SD, Ivanovich P, Remuzzi G, et al
    Metformin Use and Cardiovascular Events in Patients with Type 2 Diabetes and Chronic Kidney Disease.
    Diabetes Obes Metab. 2019 Jan 22. doi: 10.1111/dom.13642.
    PubMed     Text format     Abstract available


  65. ZOBEL EH, von Scholten BJ, Goldman B, Persson F, et al
    Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: individual effects of treatment.
    Diabetes Obes Metab. 2019 Jan 20. doi: 10.1111/dom.13638.
    PubMed     Text format     Abstract available


  66. JONES KL, Rigda RS, Buttfield MD, Hatzinikolas S, et al
    Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycemia in health and type 2 diabetes.
    Diabetes Obes Metab. 2019 Jan 9. doi: 10.1111/dom.13633.
    PubMed     Text format     Abstract available


  67. BORG MJ, Jones KL, Sun Z, Horowitz M, et al
    Metformin attenuates the postprandial fall in blood pressure in type 2 diabetes.
    Diabetes Obes Metab. 2019 Jan 7. doi: 10.1111/dom.13632.
    PubMed     Text format     Abstract available


  68. GALLO S, Charbonnel B, Goldman A, Shi H, et al
    Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
    Diabetes Obes Metab. 2019 Jan 7. doi: 10.1111/dom.13631.
    PubMed     Text format     Abstract available


  69. NORHAMMAR A, Bodegard J, Nystrom T, Thuresson M, et al
    Dapagliflozin and Cardiovascular Mortality and Disease Outcomes in Type 2 Diabetes Patients Similar to the DECLARE-TIMI 58 Participants: A Nationwide Observational Study.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13627.
    PubMed     Text format     Abstract available


  70. GIUGLIANO D, Meier JJ, Esposito K
    Heart failure and type 2 diabetes: From CVOTs, with hope.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13629.
    PubMed     Text format     Abstract available


  71. FAN W, Song Y, Inzucchi SE, Sperling L, et al
    Composite Cardiovascular Risk Factor Target Achievement and its Predictors in US Adults with Diabetes: The Diabetes Collaborative Registry.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13625.
    PubMed     Text format     Abstract available


  72. FRIAS JP, Zimmer Z, Lam RLH, Lic GA, et al
    Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin up-titration in treatment of patients with type 2 diabetes: the CompoSIT-M Study.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13626.
    PubMed     Text format     Abstract available


    December 2018
  73. WANG C, Xiao Y, Wang J, Hou N, et al
    Dynamic Changes in Insulin and Glucagon During Disease Progression in Rhesus Monkeys with Obesity-Related Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Dec 21. doi: 10.1111/dom.13624.
    PubMed     Text format     Abstract available


  74. HEISE T, Meiffren G, Alluis B, Seroussi C, et al
    BioChaperone Lispro (BCLIS) vs faster aspart (FIA) and insulin aspart (ASP) in patients with type 1 diabetes on continuous subcutaneous insulin infusion: a randomized euglycemic clamp study.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13621.
    PubMed     Text format     Abstract available


  75. PAWASKAR M, Pinar Bilir S, Kowal S, Gonzalez C, et al
    Cost-effectiveness of intensification with SGLT2i in Type 2 Diabetes patients on metformin and sitagliptin compared to direct intensification with insulin in the United Kingdom.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13618.
    PubMed     Text format     Abstract available


  76. CHEN W, Zhou Y, Kong Z, Wang X, et al
    The Renoprotective Effects of SGLT2 Inhibitors versus Placebo in Patients with Type 2 Diabetes with or without Prevalent Kidney Disease: A Systematic Review and Meta-analysis.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13620.
    PubMed     Text format     Abstract available


  77. SINGH P, Pesavento TE, Washburn K, Walsh D, et al
    Largest single-center experience of dulaglutide for the management of diabetes mellitus in solid organ transplant.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13619.
    PubMed     Text format     Abstract available


  78. RETNAKARAN R, Ye C, Kramer CK
    Stability of Insulin and C-peptide Measurement with Long-term Frozen Storage of Serum: Implications for Diabetes Research Studies.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13617.
    PubMed     Text format     Abstract available


  79. TIBALDI J, Hadley-Brown M, Liebl A, Haldrup S, et al
    A comparative effectiveness study of degludec and insulin glargine 300U/mL in insulin-naive patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Dec 15. doi: 10.1111/dom.13616.
    PubMed     Text format     Abstract available


  80. HOLMES RS, Crabtree E, McDonagh MS
    Comparative effectiveness and harms of long-acting insulins for Type 1 and Type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Dec 15. doi: 10.1111/dom.13614.
    PubMed     Text format     Abstract available


  81. ABDURRACHIM D, Teo XQ, Woo CC, Ong SY, et al
    Cardiac metabolic modulation upon low-carbohydrate low-protein ketogenic diet in diabetic rats studied in vivo using hyperpolarized (13) C pyruvate, butyrate, and acetoacetate probes.
    Diabetes Obes Metab. 2018 Dec 11. doi: 10.1111/dom.13608.
    PubMed     Text format     Abstract available


  82. BIRKELAND KI, Bodegard J, Norhammar A, Kuiper JG, et al
    How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population? A Large European Observational study.
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13612.
    PubMed     Text format     Abstract available


  83. KLONOFF DC, Evans ML, Lane W, Kempe HP, et al
    A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13610.
    PubMed     Text format     Abstract available


  84. WU S, Gao L, Cipriani A, Huang Y, et al
    The effects of incretin-based therapies on beta-cell function and insulin resistance in type 2 diabetes: a systematic review and network meta-analysis combining 360 trials.
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13613.
    PubMed     Text format     Abstract available


  85. KUHADIYA ND, Prohaska B, Ghanim H, Dandona P, et al
    Addition of GLP-1RA therapy to Insulin in C-peptide Positive Patients With Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13609.
    PubMed     Text format     Abstract available


  86. HALAMA A, Kahal H, Bhagwat AM, Zierer J, et al
    The metabolic and proteomic signatures of hypoglycemia in type 2 diabetes.
    Diabetes Obes Metab. 2018 Dec 7. doi: 10.1111/dom.13602.
    PubMed     Text format     Abstract available


  87. OWENS DR, Landgraf W, Frier BM, Zhang M, et al
    Commencing insulin glargine 100 U/mL therapy in people with type 2 diabetes: Determinants of achievement of HbA1c goal <7.0.
    Diabetes Obes Metab. 2018 Dec 6. doi: 10.1111/dom.13607.
    PubMed     Text format     Abstract available


  88. MODY R, Huang Q, Yu M, Zhao R, et al
    Adherence, Persistence, Glycemic Control and Costs Among Patients with Type 2 Diabetes Initiating Dulaglutide Compared with Liraglutide or Exenatide QW at 12 Months Follow-Up in a US Real-World Setting.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13603.
    PubMed     Text format     Abstract available


  89. CHILTON RJ, Oliveros R, Gallegos KM, Pham S, et al
    PCSK9 inhibitors and diabetes: translational biology to clinical practice.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13600.
    PubMed     Text format     Abstract available


  90. WATSON LE, Phillips LK, Wu T, Bound MJ, et al
    A whey/guar "preload" improves postprandial glycaemia and HbA1c in type 2 diabetes - a 12-week, single-blind, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13604.
    PubMed     Text format     Abstract available


  91. WITTERT G, Atlantis E, Allan C, Bracken K, et al
    Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomised controlled trial.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13601.
    PubMed     Text format     Abstract available


    November 2018
  92. HANDELSMAN Y, Mathieu C, Del Prato S, Johnsson E, et al
    Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13594.
    PubMed     Text format     Abstract available


  93. WATADA H, Shiramoto M, Ueda S, Tang W, et al
    Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Combination with Insulin in Japanese Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13593.
    PubMed     Text format     Abstract available


  94. MONAMI M, Sesti G, Mannucci E
    PCSK9 Inhibitor Therapy: A Systematic Review And Meta-Analysis of Metabolic And Cardiovascular Outcomes in Patients With Diabetes.
    Diabetes Obes Metab. 2018 Nov 28. doi: 10.1111/dom.13599.
    PubMed     Text format     Abstract available


  95. MOSER O, Pandis M, Aberer F, Kojzar H, et al
    A head-to-head comparison of personal and professional continuous glucose monitoring systems in people with type 1 diabetes: hypoglycaemia remains the weak spot.
    Diabetes Obes Metab. 2018 Nov 28. doi: 10.1111/dom.13598.
    PubMed     Text format     Abstract available


  96. BIESTER T, Nir J, Remus K, Farfel A, et al
    DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control using the MD-Logic automated insulin delivery system compared to sensor augmented pump therapy in patients with type 1 diabete
    Diabetes Obes Metab. 2018 Nov 26. doi: 10.1111/dom.13585.
    PubMed     Text format     Abstract available


  97. XIANG Y, Huang G, Zhu Y, Zuo X, et al
    Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin requiring diabetes in China: a population based multicenter national wide survey.
    Diabetes Obes Metab. 2018 Nov 24. doi: 10.1111/dom.13595.
    PubMed     Text format     Abstract available


  98. VELLANKI P, Rasouli N, Baldwin D, Alexanian S, et al
    Glycaemic Efficacy and Safety of Linagliptin compared to Basal-Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non-Cardiac Surgery: A Multicenter Randomized Clinical Trial.
    Diabetes Obes Metab. 2018 Nov 20. doi: 10.1111/dom.13587.
    PubMed     Text format     Abstract available


  99. SOKOLOV V, Yakovleva T, Ueda S, Parkinson J, et al
    Urinary glucose excretion after dapagliflozin treatment: an exposure-response modeling comparison between Japanese and non-Japanese patients diagnosed with Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Nov 19. doi: 10.1111/dom.13586.
    PubMed     Text format     Abstract available


  100. CUSI K, Bril F, Barb D, Polidori D, et al
    Effect of Canagliflozin Treatment on Hepatic Triglyceride Content and Glucose Metabolism in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Nov 16. doi: 10.1111/dom.13584.
    PubMed     Text format     Abstract available


  101. JENSEN J, Schou M, Kistorp C, Faber J, et al
    Prevalence of heart failure and diagnostic value of MR-proANP in outpatients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Nov 16. doi: 10.1111/dom.13583.
    PubMed     Text format     Abstract available


  102. BARER Y, Cohen O, Cukierman-Yaffe T
    The effect of glycemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease - a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Nov 13. doi: 10.1111/dom.13581.
    PubMed     Text format     Abstract available


  103. BONADONNA RC, Yale JF, Brulle-Wohlhueter C, Boelle-Le Corfec E, et al
    Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3.
    Diabetes Obes Metab. 2018 Nov 9. doi: 10.1111/dom.13578.
    PubMed     Text format     Abstract available


  104. JADAWJI C, Crasto W, Gillies C, Kar D, et al
    Prevalence and progression of diabetic nephropathy in South Asians, White Europeans and Afro-Caribbeans with Type 2 diabetes; a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Nov 8. doi: 10.1111/dom.13569.
    PubMed     Text format     Abstract available


  105. VAN BRUGGEN FH, Luijendijk HJ
    What the diabetes data in FOURIER trial fail to show.
    Diabetes Obes Metab. 2018 Nov 8. doi: 10.1111/dom.13576.
    PubMed     Text format     Abstract available


  106. MASON SA, Rasmussen B, van Loon LJC, Salmon J, et al
    Ascorbic acid supplementation improves postprandial glycaemic control and blood pressure in people with type 2 diabetes: Findings of a randomized cross-over trial.
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13571.
    PubMed     Text format     Abstract available


  107. WOO V, Bell A, Clement M, Noronha L, et al
    CANadian CAnagliflozin Registry: Effectiveness and Safety of Canagliflozin in the treatment of Type 2 diabetes mellitus in Canadian Clinical Practice.
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13573.
    PubMed     Text format     Abstract available


  108. ITOH H, Komuro I, Takeuchi M, Akasaka T, et al
    Achieving LDL-C target levels less than 70 mg/dL may provide extra cardiovascular protection in high-risk patients: exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients With Hypercholesterolemia and Diabetic Retinopathy St
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13575.
    PubMed     Text format     Abstract available


  109. ROUSSEL R, Duran Garcia S, Zhang Y, Shah S, et al
    Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13574.
    PubMed     Text format     Abstract available


    October 2018
  110. BORG MJ, Bound M, Grivell J, Sun Z, et al
    Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes.
    Diabetes Obes Metab. 2018 Oct 28. doi: 10.1111/dom.13567.
    PubMed     Text format     Abstract available


  111. DAVIS TME, Bruce DG, Finn J, Curtis BH, et al
    Temporal changes in the incidence and predictors of severe hypoglycaemia in type 2 diabetes: The Fremantle Diabetes Study.
    Diabetes Obes Metab. 2018 Oct 28. doi: 10.1111/dom.13568.
    PubMed     Text format     Abstract available


  112. KIM Y, Kang ES, Jang HC, Kim DJ, et al
    Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
    Diabetes Obes Metab. 2018 Oct 26. doi: 10.1111/dom.13566.
    PubMed     Text format     Abstract available


  113. DEVRIES JH, Bailey TS, Bhargava A, Gerety G, et al
    Day-to-day Fasting Self-monitored Blood Glucose Variability is Associated with Risk of Hypoglycaemia in Insulin-Treated Patients with Type 1 and Type 2 Diabetes: A Post Hoc Analysis of the SWITCH Trials.
    Diabetes Obes Metab. 2018 Oct 25. doi: 10.1111/dom.13565.
    PubMed     Text format     Abstract available


  114. VILJOEN A, Hoxer CS, Johansen P, Malkin S, et al
    Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK.
    Diabetes Obes Metab. 2018 Oct 25. doi: 10.1111/dom.13564.
    PubMed     Text format     Abstract available


  115. HOVELMANN U, Braendholt Olsen M, Mouritzen U, Lamers D, et al
    Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2018 Oct 23. doi: 10.1111/dom.13562.
    PubMed     Text format     Abstract available


  116. ABERER F, Lichtenegger KM, Smajic E, Donsa K, et al
    GlucoTab guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalised patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Oct 16. doi: 10.1111/dom.13559.
    PubMed     Text format     Abstract available


  117. AL-QAISSI A, Papageorgiou M, Javed Z, Heise T, et al
    Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13555.
    PubMed     Text format     Abstract available


  118. BJORNSTAD P, Singh SK, Snell-Bergeon JK, Lovshin JA, et al
    The Relationships between Markers of Tubular Injury and Intrarenal Hemodynamic Function in Adults with and without Type 1 Diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13556.
    PubMed     Text format     Abstract available


  119. CHO KYG, Nakamura A, Omori K, Takase T, et al
    Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13557.
    PubMed     Text format     Abstract available


  120. BAIN SC, Mosenzon O, Arechavaleta R, Bogdanski P, et al
    Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
    Diabetes Obes Metab. 2018 Oct 4. doi: 10.1111/dom.13553.
    PubMed     Text format     Abstract available


  121. GARCIA-FINANA M, Hughes DM, Cheyne CP, Broadbent DM, et al
    Personalized risk-based screening for diabetic retinopathy: a multivariate approach vs. the use of stratification rules.
    Diabetes Obes Metab. 2018 Oct 3. doi: 10.1111/dom.13552.
    PubMed     Text format     Abstract available


  122. MAGALHAES JP, Judice PB, Ribeiro R, Andrade R, et al
    Effectiveness of high intensity interval training combined with resistance training vs. continuous moderate intensity training combined with resistance training in patients with type 2 diabetes - 1 year randomized controlled trial.
    Diabetes Obes Metab. 2018 Oct 3. doi: 10.1111/dom.13551.
    PubMed     Text format     Abstract available


  123. PEARCE I, Simo R, Lovestam-Adrian M, Wong DT, et al
    Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review.
    Diabetes Obes Metab. 2018 Oct 2. doi: 10.1111/dom.13550.
    PubMed     Text format     Abstract available


  124. MULDER S, Hamidi H, Kretzler M, Ju W, et al
    An integrative systems biology approach for precision medicine in diabetic kidney disease.
    Diabetes Obes Metab. 2018;20 Suppl 3:6-13.
    PubMed     Text format     Abstract available


  125. DE VRIES JK, Levin A, Loud F, Adler A, et al
    Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives.
    Diabetes Obes Metab. 2018;20 Suppl 3:24-29.
    PubMed     Text format     Abstract available


  126. MOL PGM, Thompson A, Heerspink HJL, Leufkens HGM, et al
    Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.
    Diabetes Obes Metab. 2018;20 Suppl 3:19-23.
    PubMed     Text format     Abstract available


  127. HEERSPINK HJL, de Zeeuw D
    Treating diabetic complications; from large randomized clinical trials to precision medicine.
    Diabetes Obes Metab. 2018;20 Suppl 3:3-5.
    PubMed     Text format     Abstract available


  128. HEERSPINK HJL, List J, Perkovic V
    New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.
    Diabetes Obes Metab. 2018;20 Suppl 3:14-18.
    PubMed     Text format     Abstract available


    September 2018
  129. AL-QAISSI A, Papageorgiou M, Deshmukh H, Madden LA, et al
    The effects of acute insulin-induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes.
    Diabetes Obes Metab. 2018 Sep 28. doi: 10.1111/dom.13548.
    PubMed     Text format     Abstract available


  130. NAUCK MA, Buse JB, Mann JFE, Pocock S, et al
    Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.
    Diabetes Obes Metab. 2018 Sep 27. doi: 10.1111/dom.13547.
    PubMed     Text format     Abstract available


  131. BUSE JB, Carlson AL, Komatsu M, Mosenzon O, et al
    Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial.
    Diabetes Obes Metab. 2018 Sep 26. doi: 10.1111/dom.13545.
    PubMed     Text format     Abstract available


  132. LIAKOS A, Lambadiari V, Bargiota A, Kitsios K, et al
    Effect of liraglutide on ambulatory blood pressure in hypertensive patients with type 2 diabetes: randomized, double blind, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Sep 22. doi: 10.1111/dom.13541.
    PubMed     Text format     Abstract available


  133. BAIN SC, Klufas MA, Ho A, Matthews DR, et al
    Worsening diabetic retinopathy with rapid improvement in systemic glucose control: a review.
    Diabetes Obes Metab. 2018 Sep 18. doi: 10.1111/dom.13538.
    PubMed     Text format     Abstract available


  134. SEUFERT J, Fritsche A, Pscherer S, Anderten H, et al
    Titration and optimization trial for the initiation of insulin glargine 100 U/mL in inadequately controlled type-2 diabetes patients on oral antidiabetic drugs.
    Diabetes Obes Metab. 2018 Sep 18. doi: 10.1111/dom.13535.
    PubMed     Text format     Abstract available


  135. ABDURRACHIM D, Teo XQ, Woo CC, Chan WX, et al
    Empagliflozin lowers myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized (13) C magnetic resonance spectroscopy study.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13536.
    PubMed     Text format     Abstract available


  136. NICHOLS GA, Philip S, Reynolds K, Granowitz CB, et al
    Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13537.
    PubMed     Text format     Abstract available


  137. MOSER O, Eckstein ML, Mueller A, Birnbaumer P, et al
    Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: a randomised cross-over trial.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13534.
    PubMed     Text format     Abstract available


  138. KUO S, Yang CT, Wu JS, Ou HT, et al
    Effects of intensifying triple oral antidiabetic drug therapy by initiating insulin versus enhancing oral antidiabetic drug therapy on clinical outcomes in patients with type 2 diabetes: a nationwide population-based, propensity score-matched cohort s
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13525.
    PubMed     Text format     Abstract available


  139. SINGH RG, Nguyen NN, DeSouza SV, Pendharkar SA, et al
    Comprehensive analysis of body composition and insulin traits associated with intra-pancreatic fat deposition in health and new-onset prediabetes/diabetes after acute pancreatitis.
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13523.
    PubMed     Text format     Abstract available


  140. YOSHIKAWA F, Kumashiro N, Shigiyama F, Uchino H, et al
    Efficacy of Intermittent Empagliflozin Supplementation on Dietary Self-Management and Glycemic Control in Patients With Poorly Controlled Type 2 Diabetes: A 24-Week Randomized Controlled Trial.
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13524.
    PubMed     Text format     Abstract available


  141. SHIMIZU M, Suzuki K, Kato K, Jojima T, et al
    Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13520.
    PubMed     Text format     Abstract available


  142. YU M, Shankar RR, Zhang R, Zhang Y, et al
    Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with pre-mixed insulin.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13517.
    PubMed     Text format     Abstract available


  143. NATALI A, Nesti L, Venturi E, Shore AC, et al
    Metformin is the key factor for elevated plasma GDF-15 levels in type 2 diabetes: a nested, case-control study.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13519.
    PubMed     Text format     Abstract available


  144. KHUNTI K, Seidu S, Davies MJ
    Should sodium glucose co-transporter 2 inhibitors be considered as first line oral therapy for people with type 2 diabetes?
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13518.
    PubMed     Text format     Abstract available


  145. IDRIS I
    News and Views for September 2018: Highlights from the American Diabetes Association Scientific meeting, June 2018.
    Diabetes Obes Metab. 2018;20:2321-2324.
    PubMed     Text format    


  146. RIAHI Y, Israeli T, Cerasi E, Leibowitz G, et al
    Effects of proinsulin misfolding on beta-cell dynamics, differentiation and function in diabetes.
    Diabetes Obes Metab. 2018;20 Suppl 2:95-103.
    PubMed     Text format     Abstract available


  147. FOLLI F, La Rosa S, Finzi G, Davalli AM, et al
    Pancreatic islet of Langerhans' cytoarchitecture and ultrastructure in normal glucose tolerance and in type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018;20 Suppl 2:137-144.
    PubMed     Text format     Abstract available


  148. MESZAROS G, Pasquier A, Vivot K, Goginashvili A, et al
    Lysosomes in nutrient signalling: A focus on pancreatic beta-cells.
    Diabetes Obes Metab. 2018;20 Suppl 2:104-115.
    PubMed     Text format     Abstract available


  149. LIU M, Weiss MA, Arunagiri A, Yong J, et al
    Biosynthesis, structure, and folding of the insulin precursor protein.
    Diabetes Obes Metab. 2018;20 Suppl 2:28-50.
    PubMed     Text format     Abstract available


  150. NAPOLITANO T, Silvano S, Vieira A, Balaji S, et al
    Role of ghrelin in pancreatic development and function.
    Diabetes Obes Metab. 2018;20 Suppl 2:3-10.
    PubMed     Text format     Abstract available


  151. ESGUERRA JLS, Nagao M, Ofori JK, Wendt A, et al
    MicroRNAs in islet hormone secretion.
    Diabetes Obes Metab. 2018;20 Suppl 2:11-19.
    PubMed     Text format     Abstract available


  152. WEI FY, Tomizawa K
    tRNA modifications and islet function.
    Diabetes Obes Metab. 2018;20 Suppl 2:20-27.
    PubMed     Text format     Abstract available


  153. THOMAIDOU S, Zaldumbide A, Roep BO
    Islet stress, degradation and autoimmunity.
    Diabetes Obes Metab. 2018;20 Suppl 2:88-94.
    PubMed     Text format     Abstract available


  154. PETRENKO V, Philippe J, Dibner C
    Time zones of pancreatic islet metabolism.
    Diabetes Obes Metab. 2018;20 Suppl 2:116-126.
    PubMed     Text format     Abstract available


  155. ALVELOS MI, Juan-Mateu J, Colli ML, Turatsinze JV, et al
    When one becomes many-Alternative splicing in beta-cell function and failure.
    Diabetes Obes Metab. 2018;20 Suppl 2:77-87.
    PubMed     Text format     Abstract available


    August 2018
  156. BOLLI GB, Wysham C, Fisher M, Chevalier S, et al
    A post hoc pooled analysis to evaluate hypoglycaemia risk with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in people with type 2 diabetes on a basal-only insulin regimen.
    Diabetes Obes Metab. 2018 Aug 29. doi: 10.1111/dom.13515.
    PubMed     Text format     Abstract available


  157. GRANADOS A, Gebremariam A, Gidding SS, Terry JG, et al
    Association of Abdominal Muscle Composition with Prediabetes and Diabetes: The CARDIA Study.
    Diabetes Obes Metab. 2018 Aug 29. doi: 10.1111/dom.13513.
    PubMed     Text format     Abstract available


  158. YU E, Ruiz-Canela M, Razquin C, Guasch-Ferre M, et al
    Changes in Arginine are Inversely Associated with Type 2 Diabetes: A Case-Cohort Study in the PREDIMED Trial.
    Diabetes Obes Metab. 2018 Aug 26. doi: 10.1111/dom.13514.
    PubMed     Text format     Abstract available


  159. BELL DSH, Goncalves E
    Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies.
    Diabetes Obes Metab. 2018 Aug 24. doi: 10.1111/dom.13512.
    PubMed     Text format     Abstract available


  160. RYAN PB, Rosenthal N
    Comment on Ryan, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 ob
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13509.
    PubMed     Text format     Abstract available


  161. ARNOLD SV, Seman L, Tang F, Peri-Okonny PA, et al
    Real-World Opportunity of Empagliflozin to Improve Blood Pressure Control in African Americans with Type 2 Diabetes: An NCDR(R) "Research-to-Practice" Project From the Diabetes Collaborative Registry (DCR).
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13510.
    PubMed     Text format     Abstract available


  162. ARNOLD SV, Yap J, Lam CSP, Tang F, et al
    Management of patients with diabetes and heart failure with reduced ejection fraction: an international comparison.
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13511.
    PubMed     Text format     Abstract available


  163. DORIS J, Millar SA, Idris I, O'Sullivan SE, et al
    Genetic Polymorphisms of the Endocannabinoid System in Obesity and Diabetes.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13504.
    PubMed     Text format     Abstract available


  164. GARIANI K, Lebowitz D, von Dach E, Kressmann B, et al
    Remission in Diabetic Foot Infections: Duration of Antibiotic Therapy and Other Possible Associated Factors.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13507.
    PubMed     Text format     Abstract available


  165. WANG W, Ruiz LN, Filippova E, Song KH, et al
    Efficacy and Safety of Once-weekly Dulaglutide Versus Insulin Glargine in Mainly Asian Patients with Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea: a 52-week Open-label, Randomized Phase 3 Trial.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13506.
    PubMed     Text format     Abstract available


  166. BLEVINS TC, Barve A, Sun B, Raiter Y, et al
    Efficacy and Safety of MYL-1501D Versus Insulin Glargine in Patients With Type 2 Diabetes After 24 Weeks: Results of the Phase 3 INSTRIDE 2 Study.
    Diabetes Obes Metab. 2018 Aug 15. doi: 10.1111/dom.13495.
    PubMed     Text format     Abstract available


  167. PARKER ED, Wittbrodt ET, McPheeters JT, Frias JP, et al
    Comparison of Healthcare Resource Utilization and Costs in Type 2 Diabetes Patients Initiating Dapagliflozin versus Sitagliptin.
    Diabetes Obes Metab. 2018 Aug 12. doi: 10.1111/dom.13502.
    PubMed     Text format     Abstract available


  168. KORSMO-HAUGEN HK, Brurberg KG, Mann J, Aas AM, et al
    Carbohydrate quantity in the dietary management of type 2 diabetes - a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Aug 11. doi: 10.1111/dom.13499.
    PubMed     Text format     Abstract available


  169. KAKU K, Haneda M, Tanaka Y, Lee G, et al
    Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Aug 9. doi: 10.1111/dom.13496.
    PubMed     Text format     Abstract available


  170. CHEN HF, Ho CA, Li CY
    Risk of heart failure in type 2 diabetes population: Comparison with non-diabetes subjects with and without coronary heart diseases.
    Diabetes Obes Metab. 2018 Aug 8. doi: 10.1111/dom.13493.
    PubMed     Text format     Abstract available


  171. BAILEY CJ, Marx N
    Cardiovascular protection in type 2 diabetes: insights from recent outcome trials.
    Diabetes Obes Metab. 2018 Aug 8. doi: 10.1111/dom.13492.
    PubMed     Text format     Abstract available


  172. CHRISTENSEN P, Meinert Larsen T, Westerterp-Plantenga M, Macdonald I, et al
    Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW).
    Diabetes Obes Metab. 2018 Aug 7. doi: 10.1111/dom.13466.
    PubMed     Text format     Abstract available


  173. ELBAZ-GREENER G, Bloch O, Kumets I, Blatt A, et al
    Endogenous GLP-1 system response is impaired during St-elevation myocardial infarction in type 2 diabetes patients.
    Diabetes Obes Metab. 2018 Aug 6. doi: 10.1111/dom.13490.
    PubMed     Text format     Abstract available


  174. BAE JC, Min KW, Kim YH, Kim KA, et al
    Efficacy and safety of fixed-dose comBination therApy with gemigLiptin (50 mg) and rosuvAstatiN (20 mg) Compared with Each monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, p
    Diabetes Obes Metab. 2018 Aug 6. doi: 10.1111/dom.13491.
    PubMed     Text format     Abstract available


  175. MATIKAINEN N, Soderlund S, Bjornson E, Pietilainen K, et al
    Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomised controlled study.
    Diabetes Obes Metab. 2018 Aug 2. doi: 10.1111/dom.13487.
    PubMed     Text format     Abstract available


  176. NEYMAN A, Nelson J, Tersey S, Mirmira RG, et al
    Persistent Elevations in Circulating INS DNA Among Subjects with Longstanding Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Aug 2. doi: 10.1111/dom.13489.
    PubMed     Text format     Abstract available


  177. OUCHI M, Oba K, Suganami H, Yoshida A, et al
    This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated".
    Diabetes Obes Metab. 2018;20:2041-2042.
    PubMed     Text format    


  178. ELVERT R, Herling AW, Bossart M, Weiss T, et al
    Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Diabetes Obes Metab. 2018;20:1836-1851.
    PubMed     Text format     Abstract available


  179. MORALES J, Assumpcao-Morales M
    The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia?
    Diabetes Obes Metab. 2018;20:1809-1811.
    PubMed     Text format     Abstract available


    July 2018
  180. LIAN J, McGhee SM, So C, Chau J, et al
    Long-term cost-effectiveness of Patient Empowerment Programme for Type 2 Diabetes Mellitus in primary care.
    Diabetes Obes Metab. 2018 Jul 29. doi: 10.1111/dom.13485.
    PubMed     Text format     Abstract available


  181. AVGERINOS I, Karagiannis T, Malandris K, Liakos A, et al
    Glucagon-like peptide 1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Jul 29. doi: 10.1111/dom.13484.
    PubMed     Text format     Abstract available


  182. RENARD E, Tubiana-Rufi N, Bonnemaison-Gilbert E, Coutant R, et al
    Closed-Loop Driven by Control-to-Range Algorithm Outperforms Threshold-Low-Glucose-Suspend Insulin Delivery on Glucose Control Albeit not on Nocturnal Hypoglycemia in Pre-pubertal Patients with Type 1 Diabetes in Supervised Hotel Setting.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13482.
    PubMed     Text format     Abstract available


  183. MOTTALIB A, Tomah S, Hafida S, Elseaidy T, et al
    Intensive Multidisciplinary Weight Management in Patients with Type 1 Diabetes and Obesity: a 1-Year Retrospective Matched Cohort Study.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13478.
    PubMed     Text format     Abstract available


  184. SCHMEDT N, Andersohn F, Walker J, Garbe E, et al
    Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: a nested case-control study.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13480.
    PubMed     Text format    


  185. TANG H, Yang K, Song Y, Han J, et al
    Meta-analysis of the association between sodium-glucose cotransporter 2 inhibitors and risk of skin cancer among patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13474.
    PubMed     Text format     Abstract available


  186. KU EJ, Lee DH, Jeon HJ, Oh TK, et al
    Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: an observational study in clinical practice.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13476.
    PubMed     Text format     Abstract available


  187. DAWWAS GK, Smith SM, Park H
    Cardiovascular Outcomes of Sodium Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13477.
    PubMed     Text format     Abstract available


  188. SCOTT R, Morgan J, Zimmer Z, Lam RLH, et al
    A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study.
    Diabetes Obes Metab. 2018 Jul 18. doi: 10.1111/dom.13473.
    PubMed     Text format     Abstract available


  189. BRUCE DG, Davis WA, Davis TM
    Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II.
    Diabetes Obes Metab. 2018 Jul 13. doi: 10.1111/dom.13469.
    PubMed     Text format     Abstract available


  190. JAVIER ESCALADA F, Halimi S, Senior PA, Bonnemaire M, et al
    Glycemic control and hypoglycemia benefits with insulin glargine 300 U/mL (Gla-300) extend to people with type 2 diabetes and mild-to-moderate renal impairment.
    Diabetes Obes Metab. 2018 Jul 13. doi: 10.1111/dom.13470.
    PubMed     Text format     Abstract available


  191. IDZERDA NMA, Persson F, Pena MJ, Brenner BM, et al
    NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.
    Diabetes Obes Metab. 2018 Jul 10. doi: 10.1111/dom.13465.
    PubMed     Text format     Abstract available


  192. KADOWAKI T, Sarai N, Hirakawa T, Taki K, et al
    Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics, and severity of renal impairment: A Japanese database analysis.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13463.
    PubMed     Text format    


  193. ROSENSTOCK J, Handelsman Y, Vidal J, Ampudia Blasco FJ, et al
    Propensity score-matched comparative analyses of simultaneously administered fixed-ratio iGlarLixi (LixiLan) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13462.
    PubMed     Text format     Abstract available


  194. WANG JL, Dong YH, Ko WC, Chang CH, et al
    Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: a population-based cohort study.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13461.
    PubMed     Text format     Abstract available


  195. HARJUTSALO V, Thomas MC, Forsblom C, Groop PH, et al
    Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes.
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13456.
    PubMed     Text format     Abstract available


  196. RIDDERSTRALE M, Rosenstock J, Andersen KR, Woerle HJ, et al
    Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13457.
    PubMed     Text format     Abstract available


  197. GUO L, Chen L, Chang B, Yang L, et al
    A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13454.
    PubMed     Text format     Abstract available


    June 2018
  198. ZULLO AR, Hersey M, Lee Y, Sharmin S, et al
    Outcomes of "Diabetes-Friendly" versus "Diabetes-Unfriendly" Beta-blockers in Older Nursing Home Residents with Diabetes after Acute Myocardial Infarction.
    Diabetes Obes Metab. 2018 Jun 28. doi: 10.1111/dom.13451.
    PubMed     Text format     Abstract available


  199. MULLER-WIELAND D, Kellerer M, Cypryk K, Skripova D, et al
    Efficacy and Safety of Dapagliflozin or Dapagliflozin Plus Saxagliptin Versus Glimepiride as Add-on to Metformin in Patients With Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jun 27. doi: 10.1111/dom.13437.
    PubMed     Text format     Abstract available


  200. FRIER BM, Landgraf W, Zhang M, Bolli GB, et al
    Hypoglycaemia risk in the first eight weeks of titration with insulin glargine 100 U/mL in previously insulin-naive people with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13450.
    PubMed     Text format     Abstract available


  201. SPILLER S, Bluher M, Hoffmann R
    Plasma levels of free fatty acids correlate with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13449.
    PubMed     Text format     Abstract available


  202. SULLIVAN SD, Bailey TS, Roussel R, Zhou FL, et al
    Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13345.
    PubMed     Text format     Abstract available


  203. RYAN PB, Buse JB, Schuemie MJ, DeFalco F, et al
    Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (O
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13424.
    PubMed     Text format     Abstract available


  204. WEIR DL, Abrahamowicz M, Beauchamp ME, Eurich DT, et al
    Acute vs Cumulative Benefits of Metformin use in Patients with Type 2 Diabetes and Heart Failure.
    Diabetes Obes Metab. 2018 Jun 23. doi: 10.1111/dom.13448.
    PubMed     Text format     Abstract available


  205. STEPHENSON JJ, Raval AD, Kern DM, Bae JP, et al
    Nonadherence to Basal Insulin Among Patients With Type 2 Diabetes in a US Managed Care Population: Results from a Patient Survey.
    Diabetes Obes Metab. 2018 Jun 21. doi: 10.1111/dom.13446.
    PubMed     Text format     Abstract available


  206. SUGIMOTO DH, Dex T, Stager W, Aroda VR, et al
    Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as high and low risk according to HEDIS measures.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13438.
    PubMed     Text format     Abstract available


  207. ALFREDSSON J, Green JB, Stevens SR, Reed SD, et al
    Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13377.
    PubMed     Text format     Abstract available


  208. MELMER A, Kempf P, Lunger L, Pieber TR, et al
    Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion, and ketogenesis in type 1 diabetes - a randomized, placebo-controlled, double blind, cross-over pilot study.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13439.
    PubMed     Text format     Abstract available


  209. JAIKUMKAO K, Pongchaidecha A, Chueakula N, Thongnak LO, et al
    Dapagliflozin, a SGLT2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, ER stress, and apoptosis in pre-diabetic rats.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13441.
    PubMed     Text format     Abstract available


  210. ANDERSEN G, Meiffren G, Lamers D, DeVries JH, et al
    Ultra-rapid BioChaperone Lispro Improves post-prandial Blood Glucose Excursions versus Insulin Lispro in a 14-day crossover Treatment Study in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13442.
    PubMed     Text format     Abstract available


  211. KAZIERAD DJ, Chidsey K, Somayaji VR, Bergman AJ, et al
    Efficacy and Safety of the Glucagon Receptor Antagonist PF-06291874: A 12-Week, Randomized, Dose-Response Study in Patients With Type 2 Diabetes Mellitus on Background Metformin Therapy.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13440.
    PubMed     Text format     Abstract available


  212. YAN Z, Shyr ZA, Fortunato M, Welscher A, et al
    High Fat Diet induced Remission of Diabetes in a subset of KATP -GOF Insulin Secretory-Deficient mice.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13423.
    PubMed     Text format     Abstract available


  213. KORSATKO S, Jensen L, Brunner M, Sach-Friedl S, et al
    Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in subjects with type 2 diabetes: a randomised, placebo-controlled, double-blind, crossover trial.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13422.
    PubMed     Text format     Abstract available


  214. RABBONE I, Minuto N, Toni S, Lombardo F, et al
    Insulin pump breakdown and infusion set failure in Italian children with type 1 diabetes: 1-year prospective observational study with suggestions to minimize clinical impact.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13419.
    PubMed     Text format     Abstract available


  215. TSURUTANI Y, Nakai K, Inoue K, Kosuke A, et al
    Comparative study of ipragliflozin with sitagliptin on multiple metabolic changes in Japanese patients with type 2 diabetes: a multicenter, randomized, prospective, open-label, active-controlled study.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13421.
    PubMed     Text format     Abstract available


  216. FIORETTO P, Del Prato S, Buse JB, Goldenberg R, et al
    Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Moderate Renal Impairment (Chronic Kidney Disease Stage 3A): The DERIVE Study.
    Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13413.
    PubMed     Text format     Abstract available


  217. TERAUCHI Y, Riddle MC, Hirose T, Koyama M, et al
    Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: a 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13414.
    PubMed     Text format     Abstract available


  218. EMANUEL AL, de Clercq NC, Koopen AM, van Poelgeest E, et al
    Iloprost infusion prevents the insulin-induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients.
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13410.
    PubMed     Text format     Abstract available


  219. NIMRI R, Dassau E, Segall T, Muller I, et al
    Adjusting insulin doses in patients with type 1 diabetes that use insulin pump and continuous glucose monitoring - Variations among countries and physicians.
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13408.
    PubMed     Text format     Abstract available


  220. FARR OM, Mantzoros CS
    Obese individuals with type 2 diabetes demonstrate decreased activation of the salience-related insula and increased activation of the emotion/salience-related amygdala to visual food cues compared to non-obese individuals with diabetes: a preliminary
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13403.
    PubMed     Text format     Abstract available


  221. REZNIK Y, Habteab A, Castaneda J, Shin J, et al
    Contribution of basal and postprandial hyperglycemia in type 2 diabetes patients treated by an intensified insulin regimen: impact of pump therapy in the OPT2MISE trial.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13398.
    PubMed     Text format     Abstract available


  222. HANS DEVRIES J, Desouza C, Bellary S, Unger J, et al
    Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13396.
    PubMed     Text format     Abstract available


  223. HAN KA, Chon S, Chung CH, Lim S, et al
    Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13394.
    PubMed     Text format     Abstract available


  224. KAKU K, Kuroda S, Ishida K, Umeda Y, et al
    Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: results from a randomized, phase IV study.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13397.
    PubMed     Text format     Abstract available


  225. JALVING AC, Gant CM, Binnenmars SH, Soedamah-Muthu SS, et al
    Glycemic Control In The Diabetes And Lifestyle Cohort Twente - A Cross-Sectional Assessment Of Lifestyle And Pharmacological Management On Hba1c Target Achievement.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13399.
    PubMed     Text format     Abstract available


  226. KREBS JD, Arahill J, Cresswell P, Weatherall M, et al
    The effect of additional mealtime insulin bolus using an insulin-to-protein ratio compared to to usual carbohydrate counting on postprandial glucose in those with Type 1 diabetes who usually follow a carbohydrate-restricted diet: a randomised cross-ov
    Diabetes Obes Metab. 2018 Jun 1. doi: 10.1111/dom.13392.
    PubMed     Text format     Abstract available


    May 2018
  227. GANDA OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, et al
    Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
    Diabetes Obes Metab. 2018 May 26. doi: 10.1111/dom.13384.
    PubMed     Text format     Abstract available


  228. NORONHA JC, Braunstein CR, Glenn A, Khan TA, et al
    Effect of Small Doses of Fructose and Allulose on Postprandial Glucose Metabolism in Type 2 Diabetes: A Double-blind, Randomized, Controlled, Acute Feeding Equivalence Trial.
    Diabetes Obes Metab. 2018 May 24. doi: 10.1111/dom.13374.
    PubMed     Text format     Abstract available


  229. DRUMMOND RS, Malkin S, Du Preez M, Lee XY, et al
    Management of type 2 diabetes with Fixed-Ratio combination insulin degludec/liraglutide (IDEGLIRA) versus Basal-Bolus therapy (INSULIN GLARGINE U100 PLUS INSULIN ASPART): A Short-Term Cost-Effectiveness analysis in the UK setting.
    Diabetes Obes Metab. 2018 May 24. doi: 10.1111/dom.13375.
    PubMed     Text format     Abstract available


  230. CAO B, Rosenblat JD, Brietzke E, Park C, et al
    Comparative Efficacy and Acceptability of Anti-Diabetic Agents for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Network Meta-analysis.
    Diabetes Obes Metab. 2018 May 23. doi: 10.1111/dom.13373.
    PubMed     Text format     Abstract available


  231. KAWASAKI R, Konta T, Nishida K
    Lipid-lowering medication use is associated with decreased risk of diabetic retinopathy and its treatments in patients with type 2 diabetes: a real-world observational analysis of a health claims database.
    Diabetes Obes Metab. 2018 May 22. doi: 10.1111/dom.13372.
    PubMed     Text format     Abstract available


  232. BELL DSH, Goncalves E
    Should we still be utilizing warfarin in the type 2 diabetic patient?
    Diabetes Obes Metab. 2018 May 22. doi: 10.1111/dom.13371.
    PubMed     Text format     Abstract available


  233. LESLIE RD, Pozzilli P, Peters AL, Buzzetti R, et al
    Response to the comment on Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2,-4 and -5 Trials.
    Diabetes Obes Metab. 2018 May 20. doi: 10.1111/dom.13366.
    PubMed     Text format     Abstract available


  234. SUZUKI R, Eiki JI, Moritoyo T, Furihata K, et al
    Effect of Short Term Treatment with Sitagliptin or Glibenclamide on Daily Glucose Fluctuation in Drug-naive Japanese Patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 May 17. doi: 10.1111/dom.13364.
    PubMed     Text format     Abstract available


  235. KAWAMORI R, Haneda M, Suzaki K, Cheng G, et al
    Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13352.
    PubMed     Text format     Abstract available


  236. HOME PD, Lam RLH, Carofano WL, Golm GT, et al
    Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: a randomized, open-label clinical trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13354.
    PubMed     Text format     Abstract available


  237. AHREN B, Atkin SL, Charpentier G, Warren ML, et al
    Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in SUSTAIN 1-5 trials.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13353.
    PubMed     Text format     Abstract available


  238. SHIMADA A, Hanafusa T, Yasui A, Lee G, et al
    Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13351.
    PubMed     Text format     Abstract available


  239. HOLLANDER PA, Carofano WL, Lam RLH, Golm GT, et al
    Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: a randomized, open-label clinical trial.
    Diabetes Obes Metab. 2018 May 14. doi: 10.1111/dom.13363.
    PubMed     Text format     Abstract available


  240. ANDREADIS P, Karagiannis T, Malandris K, Avgerinos I, et al
    Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 May 13. doi: 10.1111/dom.13361.
    PubMed     Text format     Abstract available


  241. BAILEY CJ
    European Medicines Agency: approval of new glucose-lowering medicines for type 2 diabetes.
    Diabetes Obes Metab. 2018 May 13. doi: 10.1111/dom.13360.
    PubMed     Text format     Abstract available


  242. PETRI KCC, Ingwersen SH, Flint A, Zacho J, et al
    Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.
    Diabetes Obes Metab. 2018 May 11. doi: 10.1111/dom.13358.
    PubMed     Text format     Abstract available


  243. CURTIN F, Bernard C, Levet S, Perron H, et al
    A new therapeutic approach for type 1 diabetes: rationale for GNbAC1 an anti-HERV-W-Env monoclonal antibody.
    Diabetes Obes Metab. 2018 May 10. doi: 10.1111/dom.13357.
    PubMed     Text format     Abstract available


  244. BLIND E, Janssen H, Dunder K, de Graeff PA, et al
    The European Medicines Agency's Approval of New Medicines for Type 2 Diabetes.
    Diabetes Obes Metab. 2018 May 8. doi: 10.1111/dom.13349.
    PubMed     Text format     Abstract available


  245. FITZPATRICK C, Chatterjee S, Seidu S, Bodicoat DH, et al
    Association of hypoglycaemia and cardiac arrhythmia risk in patients with diabetes mellitus: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 May 8. doi: 10.1111/dom.13348.
    PubMed     Text format     Abstract available


  246. CURTIS HJ, Dennis JM, Shields BM, Walker AJ, et al
    Time Trends and Geographical Variation in Prescribing of Drugs for Diabetes in England 1998-2017.
    Diabetes Obes Metab. 2018 May 7. doi: 10.1111/dom.13346.
    PubMed     Text format     Abstract available


  247. MAIORINO MI, Chiodini P, Bellastella G, Scappaticcio L, et al
    Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2018 May 7. doi: 10.1111/dom.13343.
    PubMed     Text format     Abstract available


  248. OVERBEEK J, Heintjes E, Huisman E, Tikkanen C, et al
    Clinical Effectiveness of Liraglutide versus Basal Insulin in a Real-world Setting: Evidence for Improved Glycaemic and Weight Control in Obese Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 May 3. doi: 10.1111/dom.13335.
    PubMed     Text format     Abstract available


  249. HUANG CJ, Wang WT, Sung SH, Chen CH, et al
    Blood Glucose Reduction by Diabetic Drugs with Minimal Hypoglycemia Risk for Cardiovascular Outcomes: Evidence from Meta-regression Analysis of Randomized Controlled Trials.
    Diabetes Obes Metab. 2018 May 2. doi: 10.1111/dom.13342.
    PubMed     Text format     Abstract available


    April 2018
  250. CHEN YH, Huang CN, Cho YM, Li P, et al
    Efficacy and safety of dulaglutide monotherapy compared to glimepiride in East Asian patients with type 2 diabetes in a multicenter, double-blind, randomized, parallel-arm, active comparator, phase 3 trial.
    Diabetes Obes Metab. 2018 Apr 30. doi: 10.1111/dom.13340.
    PubMed     Text format     Abstract available


  251. GOLDENBERG RM, Assimakopoulos P, Gilbert JD, Gottesman IS, et al
    A Practical Approach and Algorithm for Intensifying Beyond Basal Insulin in Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Apr 29. doi: 10.1111/dom.13337.
    PubMed     Text format     Abstract available


  252. ZHU XX, Zhu DL, Li XY, Li YL, et al
    Dorzagliatin (HMS5552), a Novel Dual Acting Glucokinase Activator, Improves Glycemic Control and Pancreatic beta-cell Function in Patients with Type 2 Diabetes: A 28-day Treatment Study Using Biomarker-Guided Patient Selection.
    Diabetes Obes Metab. 2018 Apr 29. doi: 10.1111/dom.13338.
    PubMed     Text format     Abstract available


  253. PANDEYA N, Huxley RR, Chung HF, Dobson AJ, et al
    Female reproductive history and risk of type 2 diabetes: a prospective analysis of 126,721 women.
    Diabetes Obes Metab. 2018 Apr 25. doi: 10.1111/dom.13336.
    PubMed     Text format     Abstract available


  254. WARREN M, Chaykin L, Trachtenbarg D, Nayak G, et al
    Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13331.
    PubMed     Text format     Abstract available


  255. LIU DM, Mosialou I, Liu JM
    Bone: another potential target to treat, prevent and predict diabetes.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13330.
    PubMed     Text format     Abstract available


  256. COLLIER A, Connelly PJ, Hair M, Cameron L, et al
    Mortality risk is still higher in people with type 1 diabetes: a population-based cohort study (The Ayrshirre Diabetes fOllow-up Cohort (ADOC) study).
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13334.
    PubMed     Text format     Abstract available


  257. SIDORENKOV G, van Boven JFM, Hoekstra T, Nijpels G, et al
    HbA1c response after insulin initiation in patients with type 2 diabetes in real-life: identifying distinct subgroups.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13332.
    PubMed     Text format     Abstract available


  258. OUT M, Top WMC, Lehert P, Schalkwijk CA, et al
    Long-term treatment with metformin in type 2 diabetes and vitamin D levels: A post hoc analysis of a randomised placebo-controlled trial.
    Diabetes Obes Metab. 2018 Apr 17. doi: 10.1111/dom.13327.
    PubMed     Text format    


  259. BLEVINS TC, Barve A, Sun B, Ankersen M, et al
    Efficacy and Safety of MYL-1501D Versus Insulin Glargine in Patients With Type 1 Diabetes After 52 Weeks: Results of the Phase 3 INSTRIDE 1 Study.
    Diabetes Obes Metab. 2018 Apr 15. doi: 10.1111/dom.13322.
    PubMed     Text format     Abstract available


  260. ANDERSEN ES, Lund A, Bagger JI, Andreasen C, et al
    Is glucagon-like peptide-1 fully protected by dipeptidyl peptidase 4 inhibitor administration in patients with type 2 diabetes?
    Diabetes Obes Metab. 2018 Apr 14. doi: 10.1111/dom.13321.
    PubMed     Text format     Abstract available


  261. PONTIROLI AE, Ceriani V
    Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality?
    Diabetes Obes Metab. 2018 Apr 13. doi: 10.1111/dom.13317.
    PubMed     Text format     Abstract available


  262. BARNETT AH, Arnoldini S, Hunt B, Subramanian G, et al
    Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A Long-Term Cost-Effectiveness analysis.
    Diabetes Obes Metab. 2018 Apr 13. doi: 10.1111/dom.13318.
    PubMed     Text format     Abstract available


  263. FARNGREN J, Persson M, Ahren B
    Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes-a randomized, placebo-controlled study.
    Diabetes Obes Metab. 2018 Apr 12. doi: 10.1111/dom.13316.
    PubMed     Text format     Abstract available


    March 2018
  264. HEERSPINK HJL, Andress DL, Bakris G, Brennan JJ, et al
    Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial.
    Diabetes Obes Metab. 2018 Mar 31. doi: 10.1111/dom.13315.
    PubMed     Text format     Abstract available


  265. MATHIEU C, Del Prato S, Botros FT, Thieu VT, et al
    Effect of Once Weekly Dulaglutide by Baseline Beta-cell Function in People with Type 2 Diabetes in the AWARD Programme.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13313.
    PubMed     Text format     Abstract available


  266. VOORMOLEN DN, DeVries JH, Sanson RME, Heringa MP, et al
    Continuous Glucose Monitoring during Diabetic Pregnancy (GlucoMOMS); a multicentre randomised controlled trial.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13310.
    PubMed     Text format     Abstract available


  267. RADHOLM K, Chalmers J, Ohkuma T, Peters S, et al
    Use of the waist-to-height-ratio to predict cardiovascular risk in patients with diabetes: results from ADVANCE-ON.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13311.
    PubMed     Text format     Abstract available


  268. BECKER RHA
    Comment to Heise, T, Norskov, M, Nosek, L, Kaplan, K, Famulla, S and Haahr, H. L. (2017), Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Met
    Diabetes Obes Metab. 2018 Mar 29. doi: 10.1111/dom.13308.
    PubMed     Text format     Abstract available


  269. HOU C, Xu Q, Diao S, Hewitt J, et al
    Mobile phone applications and self-management of diabetes: a systematic review with meta-analysis, meta-regression of 21 randomized trials, and GRADE.
    Diabetes Obes Metab. 2018 Mar 27. doi: 10.1111/dom.13307.
    PubMed     Text format     Abstract available


  270. ORSI E, Solini A, Bonora E, Fondelli C, et al
    Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Mar 26. doi: 10.1111/dom.13306.
    PubMed     Text format     Abstract available


  271. ARNOLD SV, Kosiborod M, Wang J, Fenici P, et al
    Burden of Cardio-Renal-Metabolic Conditions in Adults with Type 2 Diabetes within the Diabetes Collaborative Registry.
    Diabetes Obes Metab. 2018 Mar 25. doi: 10.1111/dom.13303.
    PubMed     Text format     Abstract available


  272. RUAN Y, Bally L, Thabit H, Leelarathna L, et al
    Hypoglycaemia Incidence and Recovery During Home Use of Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Mar 25. doi: 10.1111/dom.13304.
    PubMed     Text format     Abstract available


  273. REED SD, Li Y, Leal J, Radican L, et al
    Longitudinal Medical Resources and Costs Among Type 2 Diabetes Patients Participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13292.
    PubMed     Text format     Abstract available


  274. FRIAS JP, Hardy E, Ahmed A, Ohman P, et al
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13296.
    PubMed     Text format     Abstract available


  275. GUO M, Ding J, Li J, Wang J, et al
    SGLT2 inhibitors and stroke risk in patients with type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13295.
    PubMed     Text format     Abstract available


  276. LI D, Shi W, Wang T, Tang H, et al
    SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13294.
    PubMed     Text format     Abstract available


  277. PICHE ME, Laberge AS, Brassard P, Arsenault BJ, et al
    Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: a 1 year randomized study.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13293.
    PubMed     Text format     Abstract available


  278. KIM YG, Jeon JY, Han SJ, Kim DJ, et al
    Sodium-glucose co-transporter 2 inhibitors and the risk for diabetic ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13297.
    PubMed     Text format     Abstract available


  279. MASTRACCI TL, Turatsinze JV, Book BK, Restrepo IA, et al
    Distinct Gene Expression Pathways in Islets from Individuals with Short- and Long-Duration Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13298.
    PubMed     Text format     Abstract available


  280. LAUBNER K, Riedel N, Fink K, Holl RW, et al
    Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus - a case control study.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13300.
    PubMed     Text format     Abstract available


  281. YANG YS, Lim MH, Lee SO, Roh E, et al
    Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine.
    Diabetes Obes Metab. 2018 Mar 15. doi: 10.1111/dom.13282.
    PubMed     Text format     Abstract available


  282. JONES AG, McDonald TJ
    Comment on: Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
    Diabetes Obes Metab. 2018 Mar 14. doi: 10.1111/dom.13290.
    PubMed     Text format     Abstract available


  283. MONTVIDA O, Shaw J, Blonde L, Paul SK, et al
    Long-term sustainability of glycaemic achievements with second-line anti-diabetic therapies in patients with type 2 diabetes: A real-world study.
    Diabetes Obes Metab. 2018 Mar 14. doi: 10.1111/dom.13288.
    PubMed     Text format     Abstract available


  284. POP LM, Mari A, Zhao TJ, Mitchell L, et al
    Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission.
    Diabetes Obes Metab. 2018 Mar 13. doi: 10.1111/dom.13287.
    PubMed     Text format     Abstract available


  285. BRIL F, Millan L, Kalavalpalli S, McPhaul MJ, et al
    Use of a Metabolomic Approach to Non-invasively Diagnose Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Mar 12. doi: 10.1111/dom.13285.
    PubMed     Text format     Abstract available


  286. MOHANDAS C, Bonadonna R, Shojee-Moradie F, Jackson N, et al
    Ethnic differences in insulin secretory function between Black African and White European men with early type 2 diabetes.
    Diabetes Obes Metab. 2018 Mar 8. doi: 10.1111/dom.13283.
    PubMed     Text format     Abstract available


  287. JUNG HY, Kim B, Ji Y, Ryu HG, et al
    Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice.
    Diabetes Obes Metab. 2018 Mar 8. doi: 10.1111/dom.13284.
    PubMed     Text format     Abstract available


  288. SEAQUIST ER, Dulude H, Zhang XM, Rabasa-Lhoret R, et al
    A prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycemia in adults with type 1 diabetes in a real-world setting.
    Diabetes Obes Metab. 2018 Mar 5. doi: 10.1111/dom.13278.
    PubMed     Text format     Abstract available


  289. CEA-SORIANO L, Garcia-Rodriguez LA, Brodovicz KG, Masso Gonzalez E, et al
    Safety of Non-insulin glucose-lowering drugs in pregnant women with pre-gestational diabetes: a cohort study.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13275.
    PubMed     Text format     Abstract available


  290. ALSALIM W, Persson M, Ahren B
    Different Glucagon Effects During DPP-4 Inhibition versus SGLT-2 Inhibition in Metformin-Treated Type 2 Diabetes Subjects.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13276.
    PubMed     Text format     Abstract available


  291. BJORNSTAD P, Maahs DM, Roncal CA, Snell-Bergeon JK, et al
    Role of Bicarbonate Supplementation on Urine Uric Acid Crystals and Diabetic Tubulopathy in Adults with Type 1 Diabetes: A Brief Report.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13274.
    PubMed     Text format     Abstract available


  292. HENRY RR, Muller-Wieland D, Taub PR, Bujas-Bobanovic M, et al
    Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome and without diabetes: Pooled data from 10 phase 3 trials.
    Diabetes Obes Metab. 2018 Mar 1. doi: 10.1111/dom.13273.
    PubMed     Text format     Abstract available


    February 2018
  293. HARASHIMA SI, Inagaki N, Kondo K, Maruyama N, et al
    Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: a 52-week, open-label, phase IV study.
    Diabetes Obes Metab. 2018 Feb 23. doi: 10.1111/dom.13267.
    PubMed     Text format     Abstract available


  294. GUJA C, Frias JP, Somogyi A, Jabbour S, et al
    Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study.
    Diabetes Obes Metab. 2018 Feb 23. doi: 10.1111/dom.13266.
    PubMed     Text format     Abstract available


  295. YAMADA T, Shojima N, Noma H, Yamauchi T, et al
    Sodium-glucose co-transporter 2 (SGLT2) inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2018 Feb 16. doi: 10.1111/dom.13260.
    PubMed     Text format     Abstract available


  296. HALUZIK M, Fulcher G, Pieber TR, Bardtrum L, et al
    Insulin degludec/insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia independent of baseline HbA1c levels, disease duration or BMI: A pooled meta-analysis of phase 3 studies in patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Feb 16. doi: 10.1111/dom.13261.
    PubMed     Text format     Abstract available


  297. JUNG CH, Rhee EJ, Lee WY, Min KW, et al
    A 52-week extension study of switching from gemigliptin vs. sitagliptin to gemigliptin only as an add-on to patients with type 2 diabetes inadequately controlled on metformin alone.
    Diabetes Obes Metab. 2018 Feb 13. doi: 10.1111/dom.13256.
    PubMed     Text format     Abstract available


  298. RAY KK, Leiter LA, Muller-Wieland D, Cariou B, et al
    Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
    Diabetes Obes Metab. 2018 Feb 13. doi: 10.1111/dom.13257.
    PubMed     Text format     Abstract available


  299. PANTALONE KM, Patel H, Yu M, Lando LF, et al
    Dulaglutide 1.5 mg as an Add-on Option for Patients Uncontrolled on Insulin: Subgroup Analysis by Age, Duration of Diabetes and Baseline HbA1c.
    Diabetes Obes Metab. 2018 Feb 12. doi: 10.1111/dom.13252.
    PubMed     Text format     Abstract available


  300. WONG CKH, Jiao F, Tang EHM, Tong T, et al
    Direct medical costs of diabetes mellitus in the year of mortality and year before mortality.
    Diabetes Obes Metab. 2018 Feb 12. doi: 10.1111/dom.13253.
    PubMed     Text format     Abstract available


  301. LAFFIN LJ, Bakris GL
    Results of ACCORDIAN in Accord with Lower Blood Pressure Begetting Lower Mortality in Patients with Diabetes.
    Diabetes Obes Metab. 2018 Feb 9. doi: 10.1111/dom.13249.
    PubMed     Text format     Abstract available


  302. BUCKLEY LF, Dixon DL, Wohlford GF 4th, Wijesinghe DS, et al
    Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow-Up: A Subgroup Analysis of High-Risk ACCORDION Trial Participants.
    Diabetes Obes Metab. 2018 Feb 9. doi: 10.1111/dom.13248.
    PubMed     Text format     Abstract available


  303. BALDASSARRE MPA, Andersen A, Consoli A, Knop FK, et al
    Cardiovascular biomarkers in clinical studies of type 2 diabetes.
    Diabetes Obes Metab. 2018 Feb 8. doi: 10.1111/dom.13247.
    PubMed     Text format     Abstract available


  304. GORMSEN LC, Sondergaard E, Christensen NL, Jakobsen S, et al
    Metformin does not Affect Postabsorptive Hepatic Free Fatty Acid Uptake, Oxidation or Resecretion in Humans: A 3-months Placebo Controlled Clinical Trial in Patients with Type 2 Diabetes and Healthy Controls.
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13244.
    PubMed     Text format     Abstract available


  305. HEERSPINK HJL, Andress DL, Bakris G, Brennan JJ, et al
    Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13245.
    PubMed     Text format     Abstract available


  306. KHUNTI K, Kosiborod M, Ray KK
    Legacy benefits of blood glucose, blood pressure and lipid control in people with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13243.
    PubMed     Text format     Abstract available


  307. MALMSTROM H, Walldius G, Carlsson S, Grill V, et al
    Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes - experience from the AMORIS study.
    Diabetes Obes Metab. 2018 Feb 5. doi: 10.1111/dom.13241.
    PubMed     Text format     Abstract available


  308. TRAN S, Retnakaran R, Zinman B, Kramer CK, et al
    Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
    Diabetes Obes Metab. 2018;20 Suppl 1:68-76.
    PubMed     Text format     Abstract available


  309. DANDONA P, Ghanim H, Chaudhuri A
    Incretins: Beyond type 2 diabetes.
    Diabetes Obes Metab. 2018;20 Suppl 1:59-67.
    PubMed     Text format     Abstract available


    January 2018
  310. THUESEN ACB, Vaag A
    Perspectives on diabetes mortality due to residual confounding and reverse causality by common disease.
    Diabetes Obes Metab. 2018 Jan 30. doi: 10.1111/dom.13238.
    PubMed     Text format     Abstract available


  311. POZZILLI P, Leslie RD, Peters AL, Buzzetti R, et al
    Dulaglutide Treatment Results in Effective Glycemic Control in Latent Autoimmune Diabetes in Adults (LADA): A Post-Hoc Analysis of the AWARD-2, -4, and -5 Trials.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13237.
    PubMed     Text format     Abstract available


  312. CAO YX, Liu HH, Dong QT, Li S, et al
    Effect of the PCSK9-monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13235.
    PubMed     Text format     Abstract available


  313. RETNAKARAN R, Choi H, Ye C, Kramer CK, et al
    A 2-year Trial of Intermittent Insulin Therapy versus Metformin for the Preservation of Beta-cell Function after Initial Short-term Intensive Insulin Induction in early Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13236.
    PubMed     Text format     Abstract available


  314. TANG H, Li G, Zhao Y, Wang F, et al
    Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis.
    Diabetes Obes Metab. 2018 Jan 25. doi: 10.1111/dom.13232.
    PubMed     Text format     Abstract available


  315. LIU H, Wang L, Zhang S, Leng J, et al
    One-year weight losses in the Tianjin Gestational Diabetes Mellitus Prevention Program: A Randomized Clinical Trial.
    Diabetes Obes Metab. 2018 Jan 23. doi: 10.1111/dom.13225.
    PubMed     Text format     Abstract available


  316. KREBS JD, Weatherall M, Corley B, Wiltshire E, et al
    Optimising the management of hypoglycaemia in people with Type 2 Diabetes. A randomised crossover comparison of a weight-based protocol compared with two fixed-dose glucose regimens.
    Diabetes Obes Metab. 2018 Jan 23. doi: 10.1111/dom.13231.
    PubMed     Text format     Abstract available


  317. KOFFERT J, Stahle M, Karlsson H, Iozzo P, et al
    Morbid obesity and type 2 diabetes alter intestinal fatty acid uptake and blood flow.
    Diabetes Obes Metab. 2018 Jan 20. doi: 10.1111/dom.13228.
    PubMed     Text format     Abstract available


  318. APPERLOO EM, Pena MJ, de Zeeuw D, Denig P, et al
    Individual variability in response to renin-angiotensin-aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: a primary care cohort study.
    Diabetes Obes Metab. 2018 Jan 18. doi: 10.1111/dom.13226.
    PubMed     Text format     Abstract available


  319. POLIDORI D, Iijima H, Goda M, Maruyama N, et al
    Intra- and Inter-Subject Variability for Increases in Serum Ketone Bodies in Patients With Type 2 Diabetes Treated With the Sodium Glucose Co-transporter 2 Inhibitor Canagliflozin.
    Diabetes Obes Metab. 2018 Jan 17. doi: 10.1111/dom.13224.
    PubMed     Text format     Abstract available


  320. DORENBOS E, Drummen M, Rijks J, Adam T, et al
    PREVIEW: Prevention of diabetes through lifestyle intervention in a multicentre study in Europe in children (10-17y). Design, methods, and baseline results.
    Diabetes Obes Metab. 2018 Jan 11. doi: 10.1111/dom.13216.
    PubMed     Text format     Abstract available


  321. ILANY J, Bhandari H, Nabriski D, Toledano Y, et al
    Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled on once daily basal insulin: a randomized, phase IV study.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13214.
    PubMed     Text format     Abstract available


  322. PORKSEN NK, Linnebjerg H, Lam ECQ, Garhyan P, et al
    Basal Insulin Peglispro Increases Lipid Oxidation, Metabolic Flexibility, Thermogenesis And Ketone Bodies Compared To Insulin Glargine In Subjects With Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13215.
    PubMed     Text format     Abstract available


  323. MATHIEU C, Bode BW, Franek E, Philis-Tsimikas A, et al
    Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): a 52-week, randomized, treat-to-target, phase 3 trial.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13205.
    PubMed     Text format     Abstract available


  324. TERAUCHI Y, Tamura M, Senda M, Gunji R, et al
    Long-term safety and efficacy of tofogliflozin add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13213.
    PubMed     Text format     Abstract available


  325. JABBOUR SA, Frias JP, Guja C, Hardy E, et al
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13206.
    PubMed     Text format     Abstract available


  326. MENEGHINI LF, Lee L, Gupta S, Preblick R, et al
    The association of hypoglycaemia severity and clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13208.
    PubMed     Text format     Abstract available


  327. PACKER M
    Have We Really Demonstrated the Cardiovascular Safety of Antihyperglycemic Drugs? Rethinking the Concepts of Macrovascular and Microvascular Disease in Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13207.
    PubMed     Text format     Abstract available


    December 2017
  328. PETTUS J, Reeds D, Santos Cavaiola T, Boeder S, et al
    Effect of a Glucagon Receptor Antibody (REMD-477) in Type 1 Diabetes: A Randomized Controlled Trial.
    Diabetes Obes Metab. 2017 Dec 28. doi: 10.1111/dom.13202.
    PubMed     Text format     Abstract available


  329. ZHOU FL, Xie L, Pan C, Wang Y, et al
    Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiated on basal insulin.
    Diabetes Obes Metab. 2017 Dec 26. doi: 10.1111/dom.13200.
    PubMed     Text format     Abstract available


  330. WINDING KM, Munch GW, Iepsen UW, Van Hall G, et al
    The effect of low-volume high-intensity interval training versus endurance training on glycemic control in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13198.
    PubMed     Text format     Abstract available


  331. ZHOU FL, Ye F, Berhanu P, Gupta VE, et al
    Real-world evidence on clinical and economic outcomes of switching to insulin glargine 300 Units/mL vs other basal insulins in patients with type 2 diabetes on basal insulin.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13199.
    PubMed     Text format     Abstract available


  332. BUMBU A, Moutairou A, Matar O, Fumeron F, et al
    Non-severe hypoglycemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13197.
    PubMed     Text format     Abstract available


  333. CHON S, Rhee SY, Ahn KJ, Baik SH, et al
    Long-term outcome on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed Type 2 Diabetes: A Multicentre Randomised Trial.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13196.
    PubMed     Text format     Abstract available


  334. PRATLEY RE, Eldor R, Raji A, Golm G, et al
    Ertugliflozin Plus Sitagliptin Versus Either Individual Agent Over 52 Weeks in Patients with Type 2 Diabetes Mellitus Inadequately Controlled With Metformin: The VERTIS FACTORIAL Randomized Trial.
    Diabetes Obes Metab. 2017 Dec 21. doi: 10.1111/dom.13194.
    PubMed     Text format     Abstract available


  335. WIGHTMAN SS, Sainsbury CAR, Jones GC
    Visit-to-visit HbA1c variability and systolic blood pressure (SBP) variability are significantly and additively associated with mortality in people with type 1 diabetes: an observational study.
    Diabetes Obes Metab. 2017 Dec 21. doi: 10.1111/dom.13193.
    PubMed     Text format     Abstract available


  336. PACKER M
    Role of the Sodium-Hydrogen Exchanger in Mediating the Renal Effects of Drugs Commonly Used in the Treatment of Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13191.
    PubMed     Text format     Abstract available


  337. ALSALIM W, Goransson O, Carr RD, Bizzotto R, et al
    Effect of a single dose of the DPP-4 inhibitor sitagliptin on beta-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naive, well-controlled type 2 diabetes subjects.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13192.
    PubMed     Text format     Abstract available


  338. JI L, Liu J, Yang J, Li Y, et al
    Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: analysis of results from the CONSENT trial.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13190.
    PubMed     Text format     Abstract available


  339. PRICE H, Bluher M, Prager R, Phan TM, et al
    Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13182.
    PubMed     Text format     Abstract available


  340. ZACCARDI F, Dhalwani NN, Dales J, Mani H, et al
    Comparison of glucose-lowering agents following dual therapy failure in type 2 diabetes Systematic review and network meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13185.
    PubMed     Text format     Abstract available


  341. EL KHOURY P, Roussel R, Fumeron F, Abou-Khalil Y, et al
    Plasma PCSK9 and Cardiovascular Events in Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13181.
    PubMed     Text format    


  342. HOME P, Calvi-Gries F, Blonde L, Pilorget V, et al
    Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13179.
    PubMed     Text format     Abstract available


    November 2017
  343. SISKIND D, Russell AW, Gamble C, Winckel K, et al
    Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: a randomised controlled trial.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13167.
    PubMed     Text format     Abstract available


  344. WANG H, Liu Y, Tian Q, Yang J, et al
    Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: a meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13177.
    PubMed     Text format     Abstract available


  345. LOUGHLIN AM, Qiao Q, Nunes AP, Ohman P, et al
    Effectiveness and tolerability of therapy with exenatide once-weekly versus basal insulin among injectable-naive elderly or renal impaired patients with type 2 diabetes in the United States.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13175.
    PubMed     Text format     Abstract available


  346. HART HUBERTA E, Rutten Guy E, Bontje Kyra N, Vos Rimke C, et al
    Overtreatment of older patients with type 2 diabetes mellitus in primary care.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13174.
    PubMed     Text format     Abstract available


  347. BOTHA S, Forde L, MacNaughton S, Shearer R, et al
    The effect of non-surgical weight management on weight and glycaemic control in people with type 2 diabetes: a comparison of interventional and non-interventional outcomes at three years.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13171.
    PubMed     Text format     Abstract available


  348. TAY J, Thompson CH, Luscombe-Marsh ND, Wycherley TP, et al
    Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high carbohydrate, low fat diet in type 2 diabetes: a 2 year randomized clinical trial.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13164.
    PubMed     Text format     Abstract available


  349. VILSBOLL T, Bain SC, Leiter LA, Lingvay I, et al
    Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13172.
    PubMed     Text format     Abstract available


  350. YE M, Robson PJ, Eurich DT, Vena JE, et al
    Systemic Use of Antibiotics and Risk of Diabetes in Adults: A Nested Case-control Study of Alberta's Tomorrow Project.
    Diabetes Obes Metab. 2017 Nov 20. doi: 10.1111/dom.13163.
    PubMed     Text format     Abstract available


  351. CHEN Y, Liu X, Li Q, Ma J, et al
    Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: results from the SUPER study, a randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2017 Nov 16. doi: 10.1111/dom.13161.
    PubMed     Text format     Abstract available


  352. MCGOVERN A, Tippu Z, Hinton W, Munro N, et al
    A comparison of adherence and persistence by medication class in type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2017 Nov 14. doi: 10.1111/dom.13160.
    PubMed     Text format     Abstract available


  353. TONG L, Pan C, Wang H, Bertolini M, et al
    Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: a longitudinal study of a US administrative claims database.
    Diabetes Obes Metab. 2017 Nov 8. doi: 10.1111/dom.13156.
    PubMed     Text format     Abstract available


  354. CHAN LKY, Wang Y, Ng EKW, Leung PS, et al
    NHE3 Blockade Ameliorates Type 2 Diabetes Mellitus via Inhibition of SGLT1-Mediated Glucose Absorption in the Small Intestine.
    Diabetes Obes Metab. 2017 Nov 7. doi: 10.1111/dom.13151.
    PubMed     Text format     Abstract available


  355. INAGAKI N, Harashima SI, Kaku K, Kondo K, et al
    Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2017 Nov 7. doi: 10.1111/dom.13152.
    PubMed     Text format     Abstract available


  356. JOURDAN T, Park JK, Varga ZV, Paloczi J, et al
    Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy.
    Diabetes Obes Metab. 2017 Nov 6. doi: 10.1111/dom.13150.
    PubMed     Text format     Abstract available


  357. SIEGMUND T, Tentolouris N, Knudsen ST, Lapolla A, et al
    A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes.
    Diabetes Obes Metab. 2017 Nov 6. doi: 10.1111/dom.13149.
    PubMed     Text format     Abstract available


  358. CHEN K, Kang D, Yu M, Zhang R, et al
    Direct head-to-head comparison of glycemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: a meta-analysis of long-term randomized controlled trials.
    Diabetes Obes Metab. 2017 Nov 2. doi: 10.1111/dom.13147.
    PubMed     Text format     Abstract available


  359. HERTROIJS DF, Elissen AM, Brouwers MC, Schaper NC, et al
    A risk score of BMI, HbA1c and triglycerides predicts future glycemic control in type 2 diabetes.
    Diabetes Obes Metab. 2017 Nov 2. doi: 10.1111/dom.13148.
    PubMed     Text format     Abstract available


    October 2017
  360. WITTBRODT E, Kong AM, Moore-Schiltz L, Juneau P, et al
    All-Cause and Diabetes-Related Healthcare Costs among U.S. Adults with Type 2 Diabetes Initiating Exenatide Once Weekly or Insulin Glargine.
    Diabetes Obes Metab. 2017 Oct 30. doi: 10.1111/dom.13145.
    PubMed     Text format     Abstract available


  361. SKOG O, Korsgren O
    On the etiology of type 1 diabetes: Physiological growth in children impacts disease progression.
    Diabetes Obes Metab. 2017 Oct 30. doi: 10.1111/dom.13144.
    PubMed     Text format     Abstract available


  362. KHUNTI K, Kosiborod M
    SGLT 2 inhibitors and cardiovascular outcome studies in Type 2 diabetes: From efficacy to effectiveness.
    Diabetes Obes Metab. 2017 Oct 27. doi: 10.1111/dom.13142.
    PubMed     Text format     Abstract available


  363. CASPARD H, Jabbour S, Hammar N, Fenici P, et al
    Recent Trends in the Prevalence of Type 2 Diabetes and the Association With Abdominal Obesity Lead to Growing Health Disparities in the United States.
    Diabetes Obes Metab. 2017 Oct 27. doi: 10.1111/dom.13143.
    PubMed     Text format     Abstract available


  364. GEYER MC, Rayner CK, Horowitz M, Couper JJ, et al
    Targeting Postprandial Glycaemia in Children with Diabetes: Opportunities and Challenges.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13141.
    PubMed     Text format     Abstract available


  365. HUANG J, Yang Y, Hu R, Chen L, et al
    Anti-interleukin-1 therapy has mild hypoglycemic effect in type 2 diabetes.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13140.
    PubMed     Text format     Abstract available


  366. SHAH A, Levesque K, Pierini E, Rojas B, et al
    Effect of Sitagliptin on Glucose Control in Type 2 Diabetes Mellitus after Roux-en-Y Gastric Bypass Surgery.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13139.
    PubMed     Text format     Abstract available


  367. HWANG YC, Morrow DA, Cannon CP, Liu Y, et al
    High-sensitivity C-reactive Protein, Low-Density Lipoprotein Cholesterol, and Cardiovascular Outcomes in Patients with Type 2 Diabetes in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) Trial.
    Diabetes Obes Metab. 2017 Oct 24. doi: 10.1111/dom.13136.
    PubMed     Text format     Abstract available


  368. TANG T, Abbott S, le Roux CW, Wilson V, et al
    Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis.
    Diabetes Obes Metab. 2017 Oct 20. doi: 10.1111/dom.13131.
    PubMed     Text format     Abstract available


  369. HENRY R, Rosenstock J, McCarthy JF, Carls G, et al
    Treatment Satisfaction with ITCA 650, a Novel Drug-device Delivering Continuous Exenatide versus Twice-Daily Injections of Exenatide in Type 2 Diabetics on Metformin.
    Diabetes Obes Metab. 2017 Oct 20. doi: 10.1111/dom.13133.
    PubMed     Text format     Abstract available


  370. TOP W, Stehouwer C, Lehert P, Kooy A, et al
    Metformin and beta cell function in insulin-treated patients with type 2 diabetes : a randomized placebo-controlled 4.3 year trial.
    Diabetes Obes Metab. 2017 Oct 2. doi: 10.1111/dom.13123.
    PubMed     Text format     Abstract available


    September 2017
  371. JABBOUR S, Seufert J, Scheen A, Bailey CJ, et al
    Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from Phase 2b/3 clinical trials.
    Diabetes Obes Metab. 2017 Sep 26. doi: 10.1111/dom.13124.
    PubMed     Text format     Abstract available


  372. MARFELLA R, Sardu C, Calabro P, Siniscalchi M, et al
    Non-ST-Elevation Myocardial Infarction (NSTEMI) outcome in type 2 diabetic patients with non-obstructive coronary artery stenosis: effects of incretin treatment.
    Diabetes Obes Metab. 2017 Sep 26. doi: 10.1111/dom.13122.
    PubMed     Text format     Abstract available


  373. PANG B, Zhao LH, Li XL, Song J, et al
    Different intervention strategies for preventing type 2 diabetes mellitus in China: A systematic review and network meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2017 Sep 23. doi: 10.1111/dom.13121.
    PubMed     Text format     Abstract available


  374. HULST AH, Polderman JAW, Ouweneel E, Pijl AJ, et al
    Perioperative continuation of metformin does not improve glycemic control in patients with type 2 diabetes; a randomized controlled trial.
    Diabetes Obes Metab. 2017 Sep 20. doi: 10.1111/dom.13118.
    PubMed     Text format     Abstract available


  375. DOU J, Ma J, Liu J, Wang C, et al
    Efficacy and Safety of Saxagliptin in Combination with Metformin as Initial Therapy in Chinese Patients with Type 2 diabetes: Results from the START Study, a Multicenter, Randomized, Double-blind, Active-controlled, Phase 3 Trial.
    Diabetes Obes Metab. 2017 Sep 19. doi: 10.1111/dom.13117.
    PubMed     Text format     Abstract available


  376. DAGOGO-JACK S, Liu J, Eldor R, Amorin G, et al
    Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study.
    Diabetes Obes Metab. 2017 Sep 17. doi: 10.1111/dom.13116.
    PubMed     Text format     Abstract available


  377. LEITER LA, Cariou B, Muller-Wieland D, Colhoun HM, et al
    Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
    Diabetes Obes Metab. 2017 Sep 14. doi: 10.1111/dom.13114.
    PubMed     Text format     Abstract available


  378. YUAN Z, DeFalco FJ, Ryan PB, Schuemie MJ, et al
    Risk of Lower Extremity Amputations in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors in the United States: A Retrospective Cohort Study.
    Diabetes Obes Metab. 2017 Sep 12. doi: 10.1111/dom.13115.
    PubMed     Text format     Abstract available


    March 2017
  379. NEAL B, Perkovic V, Matthews DR, Mahaffey KW, et al
    Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2017;19:387-393.
    PubMed     Text format     Abstract available


  380. DRIESSEN JH, van den Bergh JP, van Onzenoort HA, Henry RM, et al
    Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
    Diabetes Obes Metab. 2017;19:421-428.
    PubMed     Text format     Abstract available


  381. KOZLOVSKI P, Fonseca M, Mohan V, Lukashevich V, et al
    Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.
    Diabetes Obes Metab. 2017;19:429-435.
    PubMed     Text format     Abstract available


  382. CAMASTRA S, Astiarraga B, Tura A, Frascerra S, et al
    Effect of exenatide on postprandial glucose fluxes, lipolysis, and ss-cell function in non-diabetic, morbidly obese patients.
    Diabetes Obes Metab. 2017;19:412-420.
    PubMed     Text format     Abstract available


  383. KNAPEN LM, de Jong RG, Driessen JH, Keulemans YC, et al
    Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
    Diabetes Obes Metab. 2017;19:401-411.
    PubMed     Text format     Abstract available


  384. BAIN S, Druyts E, Balijepalli C, Baxter CA, et al
    Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
    Diabetes Obes Metab. 2017;19:329-335.
    PubMed     Text format     Abstract available


  385. BETTGE K, Kahle M, Abd El Aziz MS, Meier JJ, et al
    Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
    Diabetes Obes Metab. 2017;19:336-347.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: